

Vaccibody to participate at Jefferies London Healthcare Conference

Oslo, Norway, November 10, 2021 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today that its Chief Executive Officer, Michael Engsig and Chief Innovation and Strategy Officer, Agnete Fredriksen, will present at Jefferies London Healthcare Conference on November 16, 2021 at 9.40 am CET and be available for 1:1 investor meetings.

The presentation may be viewed here: <https://wsw.com/webcast/jeff201/vacc.ol/2192724>.

About Vaccibody

Vaccibody, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment cancer and infectious diseases. Vaccibody's modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses.

Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Vaccibody has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.

The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology and collaborate with Adaptive Biotechnologies for COVID-19 T cell vaccine development.

Vaccibody's shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC. Further information about Vaccibody may be found at <http://www.vaccibody.com>

Contact for Vaccibody:

CEO Michael Engsig

Vaccibody AS

Cell: +45 6173 1509

mengsig@vaccibody.com

Vaccibody AS

Oslo Science Park

Gaustadalléen 21

0349 Oslo, Norway

Forward-looking statements for Vaccibody

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.